Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Net Cash Flow (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Net Cash Flow for 8 consecutive years, with $30.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 160.92% year-over-year to $30.4 million, compared with a TTM value of -$27.7 million through Sep 2025, up 19.87%, and an annual FY2024 reading of -$43.6 million, down 90.64% over the prior year.
  • Net Cash Flow was $30.4 million for Q3 2025 at X4 Pharmaceuticals, up from -$1.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $86.7 million in Q2 2024 and bottomed at -$52.8 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$4.4 million, with a median of -$15.5 million recorded in 2025.
  • The sharpest move saw Net Cash Flow skyrocketed 654.31% in 2022, then tumbled 261.51% in 2023.
  • Year by year, Net Cash Flow stood at $5.5 million in 2021, then surged by 654.31% to $41.5 million in 2022, then crashed by 178.24% to -$32.5 million in 2023, then dropped by 27.7% to -$41.5 million in 2024, then soared by 173.37% to $30.4 million in 2025.
  • Business Quant data shows Net Cash Flow for XFOR at $30.4 million in Q3 2025, -$1.2 million in Q2 2025, and -$15.5 million in Q1 2025.